ANG Lifesciences India Yönetim

Yönetim kriter kontrolleri 3/4

ANG Lifesciences India CEO'su Rajesh Gupta, Oct2016 tarihinde atandı, in görev süresi 8.08 yıldır. şirketin hisselerinin 70.41% doğrudan sahiptir ve bu hisselerin değeri ₹ 413.94M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 5.6 yıldır.

Anahtar bilgiler

Rajesh Gupta

İcra Kurulu Başkanı

₹10.8m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	8.1yrs
CEO sahipliği	70.4%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	5.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Rajesh Gupta'un ücretlendirmesi ANG Lifesciences India'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-₹150m
Mar 31 2024	₹11m	n/a	-₹101m
Dec 31 2023	n/a	n/a	-₹111m
Sep 30 2023	n/a	n/a	-₹69m
Jun 30 2023	n/a	n/a	-₹20m
Mar 31 2023	₹11m	n/a	-₹3m
Dec 31 2022	n/a	n/a	₹96m
Sep 30 2022	n/a	n/a	₹136m
Jun 30 2022	n/a	n/a	₹238m
Mar 31 2022	₹11m	n/a	₹403m
Dec 31 2021	n/a	n/a	₹364m
Sep 30 2021	n/a	n/a	₹353m
Jun 30 2021	n/a	n/a	₹243m
Mar 31 2021	₹8m	₹8m	₹70m
Dec 31 2020	n/a	n/a	₹73m
Sep 30 2020	n/a	n/a	₹88m
Jun 30 2020	n/a	n/a	₹74m
Mar 31 2020	₹6m	₹6m	₹61m
Dec 31 2019	n/a	n/a	₹59m
Sep 30 2019	n/a	n/a	₹58m
Jun 30 2019	n/a	n/a	₹57m
Mar 31 2019	₹4m	₹4m	₹56m
Dec 31 2018	n/a	n/a	₹55m
Sep 30 2018	n/a	n/a	₹54m
Jun 30 2018	n/a	n/a	₹46m
Mar 31 2018	₹1m	₹1m	₹37m

Tazminat ve Piyasa: Rajesh 'nin toplam tazminatı ($USD 128.01K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 42.67K ).

Tazminat ve Kazançlar: Rajesh 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Rajesh Gupta (52 yo)

8.1yrs

Görev süresi

₹10,800,000

Tazminat

Mr. Rajesh Gupta has been Managing Director of ANG Lifesciences India Limited since October 1, 2016 and has been its Executive Director since June 14, 2006. Mr. Gupta founded ANG Lifesciences India Limited...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Rajesh Gupta	MD & Executive Director	8.1yrs	₹10.80m	70.41% ₹ 413.9m
Saruchi Gupta	CFO & Whole Time Director	less than a year	₹5.40m	0.19% ₹ 1.1m
Renu Kaur	Company Secretary & Compliance Officer	3.3yrs	₹568.00k	Veri yok
P.K. Sharma	Deputy General Manager of Human Resources & Administration	2.4yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

47yo

Ortalama Yaş

Deneyimli Yönetim: 540694 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Rajesh Gupta	MD & Executive Director	18.4yrs	₹10.80m	70.41% ₹ 413.9m
Saruchi Gupta	CFO & Whole Time Director	8.1yrs	₹5.40m	0.19% ₹ 1.1m
Sukhpal Singh	Independent Non Executive Director	8.5yrs	₹55.00k	0.0010% ₹ 5.9k
Chetna Verma	Non-Executive Independent Director	3.1yrs	₹60.00k	Veri yok
Harvinder Dhami	Non-Executive Independent Director	less than a year	Veri yok	Veri yok
Rohit Mittal	Non-Executive Non Independent Director	less than a year	₹25.00k	Veri yok

5.6yrs

Ortalama Görev Süresi

48.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 540694 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.6 yıldır).

ANG Lifesciences India Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

ANG Lifesciences India Limited, Annual General Meeting, Sep 30, 2024

ANG Lifesciences India Limited Announces Resignation of Neeraj Gupta as Chief Financial Officer

ANG Lifesciences India Limited Appoints Rohit Mittal as Additional Director (Non-Executive Non Independent Director)

ANG Lifesciences India Limited, Annual General Meeting, Sep 30, 2023

ANG Lifesciences India Limited Announces Resignation of Subodh Sharma as Chief Financial Officer

ANG Lifesciences India Limited, Annual General Meeting, Sep 30, 2022

Recent updates

ANG Lifesciences India Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: ₹2.35 loss per share (vs ₹1.41 profit in 1Q 2024)

ANG Lifesciences India Limited to Report Q1, 2025 Results on Aug 14, 2024

Full year 2024 earnings released: ₹7.61 loss per share (vs ₹0.20 loss in FY 2023)

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: ₹4.52 loss per share (vs ₹1.36 loss in 3Q 2023)

ANG Lifesciences India Limited to Report Q3, 2024 Results on Feb 14, 2024

New major risk - Market cap size

New major risk - Financial position

Second quarter 2024 earnings released

ANG Lifesciences India Limited Announces Resignation of Neeraj Gupta as Chief Financial Officer

ANG Lifesciences India Limited Appoints Rohit Mittal as Additional Director (Non-Executive Non Independent Director)

ANG Lifesciences India Limited, Annual General Meeting, Sep 30, 2023

First quarter 2024 earnings released: EPS: ₹1.41 (vs ₹3.19 in 1Q 2023)

ANG Lifesciences India Limited to Report Q1, 2024 Results on Aug 14, 2023

New major risk - Market cap size

Full year 2023 earnings released: EPS: ₹0.36 (vs ₹31.11 in FY 2022)

ANG Lifesciences India Limited to Report Q4, 2023 Results on May 30, 2023

Investor sentiment improves as stock rises 15%

Investor sentiment deteriorates as stock falls 20%

Investor sentiment improves as stock rises 18%

Investor sentiment deteriorates as stock falls 25%

Third quarter 2023 earnings released: ₹1.36 loss per share (vs ₹1.03 profit in 3Q 2022)

ANG Lifesciences India Limited to Report Q3, 2023 Results on Feb 14, 2023

ANG Lifesciences India Limited Announces Resignation of Subodh Sharma as Chief Financial Officer

ANG Lifesciences India Limited announced that it expects to receive INR 20 million in funding

Investor sentiment deteriorated over the past week

Second quarter 2023 earnings released

ANG Lifesciences India Limited to Report Q2, 2023 Results on Nov 14, 2022

Investor sentiment improved over the past week

ANG Lifesciences India Limited, Annual General Meeting, Sep 30, 2022

ANG Lifesciences India Limited, Annual General Meeting, Sep 30, 2022

First quarter 2023 earnings released: EPS: ₹3.99 (vs ₹13.03 in 1Q 2022)

ANG Lifesciences India Limited to Report Q1, 2023 Results on Aug 14, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: ₹39.09 (vs ₹6.78 in FY 2021)

Investor sentiment improved over the past week

ANG Lifesciences India Limited to Report Q4, 2022 Results on May 30, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

ANG Lifesciences India Limited Approves Re-Constitution of Committee

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

ANG Lifesciences India Limited (BSE:540694) agreed to acquire ANG Healthcare India Private Limited for INR 40 million.

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS ₹32.58 (vs ₹5.31 in 1H 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

ANG Lifesciences India Limited (BSE:540694) acquired Two Formulation Manufacturing Facilities from Ind-Swift Limited (BSE:524652) for INR 600 million.

Company Secretary & Compliance Officer Preeti Goel has left the company

Full year 2021 earnings released: EPS ₹13.56 (vs ₹11.76 in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: ₹84.00

ANG Lifesciences India Limited, Annual General Meeting, Dec 30, 2020

Market bids up stock over the past week

New 90-day high: ₹61.20

ANG Lifesciences India Limited to Report First Half, 2021 Results on Nov 12, 2020

New 90-day high - ₹45.95

CEO Tazminat Analizi

CEO